A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

• Published in: Clinical cancer research Vol. 30; no. 17; pp. 3768 - 3778
• Main Authors: Lentz, Robert W, Friedrich, Tyler J, Blatchford, Patrick J, Jordan, Kimberly R, Pitts, Todd M, Robinson, Hannah R, Davis, S Lindsey, Kim, Sunnie S, Leal, Alexis D, Lee, Mathew R, Waring, Meredith R N, Martin, Anne C, Dominguez, Adrian T A, Bagby, Stacey M, Hartman, Sarah J, Eckhardt, S Gail, Messersmith, Wells A, Lieu, Christopher H
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 03.09.2024
• Subjects: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzimidazoles - administration & dosage; Benzimidazoles - adverse effects; Benzimidazoles - therapeutic use; Bevacizumab - administration & dosage; Bevacizumab - adverse effects; Bevacizumab - therapeutic use; Clinical Trial Results; Clinical Trials: Immunotherapy; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Drug Resistance, Neoplasm - genetics; Female; Gastrointestinal Cancers; Humans; Immunotherapy; Male; Microsatellite Repeats; Middle Aged; Treatment Outcome

In this single-institution phase II investigator-initiated study, we assessed the ability of MAPK and VEGF pathway blockade to overcome resistance to immunotherapy in microsatellite-stable metastatic colorectal cancer (MSS mCRC). Patients with MSS, BRAF wild-type mCRC who progressed on ≥2 prior line...